Erytech Pharma
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
60 Ave Rockefeller, Lyon, Auvergne-Rhone...Website
www.erytech.comRevenue
<$5 MillionStock Symbol
ERYPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Erytech Pharma
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. Erytech Pharma Inc was established in 2004 and is headquartered in Lyon, France.Explore more
Erytech Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Erytech Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Erytech Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Erytech Pharma
Click to see if Erytech Pharma had a recent Job posting/layoffs
Check out if Erytech Pharma is spiking on competitors!
Check if Erytech Pharma has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Erytech Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Erytech Pharma recently announced quarterly report
Product Launch: Get notified when Erytech Pharma launches new products
Recommended Actions
Reach out to Masked Content who joined Erytech Pharma as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Erytech Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Erytech Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Erytech Pharma.
Erytech Pharma financials insights
Gather financial insights about Erytech Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$23.1M
Erytech Pharma Tech Stack
A closer look at the technologies used by Erytech Pharma
Most Recent Scoops
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Left Company
Executive Move
Left Company
Executive Move
Erytech Pharma News & Media
PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)
Lyon (France) and Cambridge (MA, US), 5 April 2024 – 6:00pm CEST - PHAXIAM Therapeutics (Euronext: PHXM; FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced that it has filed its Universal Registration Document with the Autorité des Marchés Financiers (AMF) in France for the financial year ending 31 December 2023. This document, including the annual financial report and the Board of Directors' report on corporPHAXIAM Therapeutics S.A. (ERYFF) Q4 2023 Earnings Call Transcript
PHAXIAM Therapeutics S.A. (OTCPK:ERYFF) Q4 2023 Earnings Conference Call March 21, 2024 9:30 AM ETCompany ParticipantsThibaut Fayet - Chief Executive...ERYTECH announces the approval of the merger with Pherecydes and reports the results of ...
ERYTECH announces the approval of the merger with Pherecydes and reports the results of the Combined Shareholder’s Meeting held on June 23, 2023 All resolutions voted with a large majority according to Board of Directors recommendationsCompany renamed Phaxiam Therapeutics, creating a world leader in phage therapy Lyon (France), June 23, 2023 – ERYTECH Pharma (Euronext Paris & Nasdaq: ERYP) announced today that all resolutions for which the Board of Directors recommended a vote in favor,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Erytech Pharma
Sign Up For FreeTo access detailed company insights
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for pa... Read More
